M402
Rheumatoid Arthritis, Inflammatory Bowel Disease, Lupus
Key Facts
About Mestag Therapeutics
Mestag Therapeutics is an early-stage biotech pioneering a novel approach in immunotherapy by targeting activated fibroblasts, a key but historically overlooked component of the tumor microenvironment and inflammatory disease sites. The company's lead asset, MST-0312, is a bispecific antibody in pre-clinical development aimed at inducing tertiary lymphoid structures (TLS) in solid tumors to enhance immune attack. A second program, M402, is developing agonist antibodies to inhibit fibroblast-driven inflammation in conditions like rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and lupus. Based in Cambridge, UK, Mestag is a private company rapidly advancing its portfolio toward the clinic.
View full company profile